Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Dysport^®, Restylane^® and Sculptra^® in Injectable Aesthetics; Aklief^®, Apprilon^®, Clobex^®, Differin/XP^®, MetroGel^®, Metvix^®, Onreltea^®, Silkis^®, TactuPump/TactuPump Forte^®, Rosiver^® and Benzac^® in Therapeutic Dermatology; and Cetaphil^®, Cetaphil Baby^® and Alastin Skincare^® in Dermatological Skincare. For more information, please visit: www.galderma.com